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ABSTRACT
Background: Trastuzumab is an active agent against human epidermal growth 
factor receptor 2 (HER2)-positive gastric cancer (GC). This study aimed to characterize 
resistance to trastuzumab-based front-line chemotherapy in HER2+ GC patients and 
to establish factors predictive of this resistance.
Results: Among 129 HER2+ GC patients, 25% displayed rapid disease 
progression within 4 months from initiation of therapy. These patients showed a 
higher rate of signet ring cell histology, bone metastasis, poor performance status, 
frequent loss of PTEN expression, and low HER2 amplification index compared with 
patients who were progression-free for at least 4 months. In contrast, there was no 
significant difference in the frequency of the PIK3R1 variant. Multivariate analyses 
confirmed two independent molecular predictors for trastuzumab resistance: loss 
of PTEN expression and low HER2 amplification index (<5). Patients with one 
or both molecular predictors at diagnosis exhibited worse progression-free and 
overall survival compared to those without risk factors (p < 0.001 and p = 0.001, 
respectively).
Conclusion: In HER2+ GC patients, loss of PTEN expression and low HER2 AI 
correlated with resistance to trastuzumab-based therapy and dismal prognosis. 
Since patients harboring these molecular predictors are unlikely to respond 
to trastuzumab-based therapy, other novel therapeutic targets needed to be 
considered.
Methods: HER2+ GC patients who were treated with trastuzumab in combination 
with either 5-fluorouracil/cisplatin or capecitabine/cisplatin were enrolled. 
Clinicopathologic features and molecular alterations of HER2, phosphoinositide 
3-kinase regulatory subunit 1 (PIK3R1), and phosphatase and tensin homolog (PTEN) 
were correlated with treatment outcome. Factors predictive of resistance were also 
explored.
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INTRODUCTION
Trastuzumab (Herceptin, Roche) is a potent anti-
HER2 humanized monoclonal antibody directed against 
HER2+ gastric cancer (GC) [1, 2]. The pivotal ToGA 
(Trastuzumab for Gastric Cancer) trial showed that 
addition of trastuzumab to conventional chemotherapy 
significantly prolongs overall survival (OS) and 
progression-free survival (PFS) in HER2+ GC compared 
with chemotherapy alone [3]. Trastuzumab-based regimen 
is now being considered as a standard front-line treatment 
for patients with HER2+ GC, and the median OS of 
these patients has risen to >12 months [3–5]. However, 
a proportion of HER2+ GC patients do not respond to 
trastuzumab-containing front-line chemotherapy ab initio, 
progressing rapidly within 3–4 months, and displaying 
dismal prognosis despite treatment [3, 6]. These patients 
with refractory malignancies seem to have primary 
(de novo) resistance and currently, detailed characterization 
of these patients and availability of surrogate marker to 
predict primary resistance remain unknown.
Activation of the PI3K signaling pathway is 
common in various human malignancies. Moreover, the 
deregulation of PI3K subunits and PTEN are well-known 
to be involved during carcinogenesis [7–9]. Specifically, a 
weakened response to trastuzumab therapy was often seen 
in HER2+ breast cancer containing activating mutations of 
the PIK3CA gene and deletions of PTEN [10, 11]. It has 
also been found that PTEN is not only a tumor suppressor, 
but also plays a critical role in trastuzumab susceptibility 
of HER2-amplified breast cancer cell lines [12]. Recently, 
PIK3R1, the regulatory subunit of PI3K, was also known 
to be involved in the activation of PI3K pathway and 
cancer progression [7, 13]. Genetic aberrations of PIK3R1 
was reported in various tumors [13–16] and, intriguingly, 
tumors lacking PIK3CA mutations tended to have frequent 
mutations in PIK3R1 [15]. PIK3R1 mutant protein is 
known to bind and stabilize PTEN, thereby suppressing 
PTEN degradation in tumor cell [13]. In a previous study 
[17], we were unable to confirm the predictive role of 
PIK3CA in HER2+ GC; therefore, here we aimed to 
identify the role of other regulators of the PI3K signaling 
pathway in HER2+ GC: PTEN and PIK3R1.
In this study, we aimed to characterize HER2+ GC 
patients with resistance to trastuzumab-based therapy 
by focusing on the PI3K pathway, in order to establish 
molecular predictive factors for primary resistance.
RESULTS
Baseline patient characteristics
For 10 years, a total of 129 HER2+ GC patients 
were enrolled and treated with either trastuzumab/XP 
or trastuzumab/FP as a first-line chemotherapy. The 
clinicopathologic and molecular characteristics of HER2+ 
GC patients are summarized in Table 1. The median age 
at diagnosis was 59 years (range: 30–84) and the male-
to-female ratio was 2.9:1. Two-thirds of patients initially 
presented with distant metastases, whereas cancer recurred 
after previous curative gastrectomy in the remaining third. 
The most frequent metastatic site was the liver (41.1%), 
followed by peritoneum (34.9%), lung (12.4%) and bone 
(11.6%). 
HER2, PTEN, and PIK3R1 status and their 
association with patient characteristics
HER2 expression in IHC staining was 3+ in 98 
(76.0%) patients and 2+ in the remaining 31 (24.0%) 
patients. The mean amplification index (AI) of HER2 
expression determined by FISH analysis was 7.0. The 
median follow-up duration was 23.8 months (range 0.9–
61.8). We observed intact PTEN expression in 83.6% of 
GC tissues and loss of PTEN expression in 16.4% of GC 
tissues. The PIK3R1 wildtype allele (GG) was identified 
in 76.8% of patients, while the remaining 23.2% had a 
variant allele (GA or AA). 
In 129 trastuzumab-treated patients, median PFS 
was 7.4 months and median OS was 16.0 months. Because 
there is no consensus on the criteria for dividing GC 
patients into trastuzumab-sensitive or -resistant, the lower 
quartile value of PFS (4.0 months) was used as a cut-
off value to distinguish between patients who benefitted 
clinically from trastuzumab and those who did not. As a 
result, 32 patients (25%) with PFS shorter than 4 months 
were classified as resistant and 97 patients (75%) with 
more than 4 months, as sensitive.
The association between clinicopathological 
and molecular features in trastuzumab-resistant 
patients are also summarized in Table 1. In HER2+ 
GC patients with primary resistance, increased 
signet ring cell (SRC) histology (21.9% vs. 6.2%, 
p = 0.031) and a higher frequency of initial bone 
metastasis (25.0% vs. 7.2%, p < 0.025) was observed 
along with poor performance status (ECOG ≥2: 
18.7% vs. 9.2%, p = 0.001). Notably, the existence 
of initial bone metastasis was highly associated with 
poor performance status (p = 0.002), suggesting that 
bone metastasis in GC severely impairs the patient’s 
activities of daily living. The average AI of HER2 in 
FISH analysis was significantly lower in patients with 
primary resistance compared with sensitive patients 
(7.7 ± 6.3 vs. 4.1 ± 1.4, p = 0.005). Moreover, loss of 
PTEN expression was more common in trastuzumab-
resistant HER2+ GC patients than in those who were 
sensitive to treatment (38.5% vs. 11.1%, p = 0.017). 
However, there was no significant difference in the 
frequency of the PIK3R1 variant allele between patients 
with and without trastuzumab-resistance.
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Table 1: Clinicopathologic features of HER2+ gastric cancer 
All patients  (n = 129) Trastuzumab-resistant patient  (n = 32)
Trastuzumab-sensitive 
patients (n = 97) P-value
Age at diagnosis 59 (30-84) 60 (30-82) 58 (32-84) 0.623
Sex 0.931
 Male 96 (74.4%) 24 (75.0%) 72 (74.2%)
 Female 33 (25.6%) 8 (25.0%) 25 (25.8%)
Histology 0.031
 Adeno, WD 7 (5.4%) 0 (0%) 7 (7.2%)
 Adeno, MD 76 (58.9%) 16 (50.0%) 60 (61.9%)
 Adeno, PD 33 (25.6%) 9 (28.1%) 24 (24.7%)
 SRC carcinoma 13 (10.1%) 7 (21.9%) 6 (6.2%)
Previous surgery 0.491
 Yes 42 (32.6%) 12 (37.5%) 30 (30.9%)
 No 87 (67.4%) 20 (62.5%) 67 (69.1%)
Location of tumor 0.420
 Proximal 31 (24.0%) 6 (18.8%) 25 (25.8%)
 Distal 98 (76.0%) 26 (81.3%) 72 (74.2%)
Peritoneal metastasis 0.225
 Yes 45 (34.9%) 14 (43.8%) 31 (32.0%)
 No 84 (65.1%) 18 (56.3%) 66 (68.0%)
Liver metastasis 0.951
 Yes 53 (41.1%) 13 (40.6%) 40 (41.2%)
 No 76 (58.9%) 19 (59.4%) 57 (58.8%)
Bone metastasis 0.025
 Yes 15 (11.6%) 8 (25.0%) 7 (7.2%)
 No 104 (80.6%) 22 (68.8%) 82 (84.5%)
 N/A 10 (7.8%) 2 (6.3%) 8 (8.2%)
Lung metastasis 0.985
 Yes 16 (12.4%) 4 (12.5%) 12 (12.4%)
 No 113 (87.6%) 28 (87.5%) 85 (87.6%)
Performance status 0.001
 ECOG 0 72 (55.8%) 8 (25.0%) 64 (66.0%)
 ECOG 1 42 (32.6%) 18 (56.3%) 24 (24.7%)
 ECOG ≥2 15 (11.7%) 6 (18.7%) 9 (9.2%)
Regimen 0.896
 Herceptin-FP 17 (13.2%) 4 (12.5%) 13 (13.4%)
 Herceptin-XP 112 (86.8%) 28 (87.5%) 84 (86.6%)
HER2 IHC 0.475
 2+ 31 (24.0%) 10 (31.3%) 21 (21.6%)
 3+ 98 (76.0%) 22 (68.8%) 76 (78.4%)
HER2 amplification index 7.0 ± 5.9 7.7 ± 6.3 4.1 ± 1.4 0.005
PTEN expression 0.017
 Loss 11 (16.4%) 5 (38.5%) 6 (11.1%)
 Intact 56 (83.6%) 8 (61.5%) 48 (88.9%)
PIK3R1 genotype 0.460
 Variant 16 (23.2%) 5 (31.3%) 12 (22.2%)
 Wildtype 53 (76.8%) 11 (68.8%) 42 (77.8%)
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HER2 and PTEN status and clinical response to 
trastuzumab-based therapy
Next, we analyzed clinical outcomes according to 
the molecular characteristics of HER2+ GC. In terms of 
tumor response to first-line therapy (Table 2), objective 
response rate was significantly increased in patients with 
HER2 AI ≥5 compared to those with AI <5 (58.8% vs. 
21.4%, p = 0.002). At the same time, objective response 
rate tended to decrease in patients with a loss of PTEN 
compared to those with intact PTEN expression (64.3% 
vs. 36.4%, p = 0.220).
Low HER2 amplification index and loss of PTEN 
expression predict resistance to trastuzumab-
based first-line chemotherapy
To identify the factors predictive of response to 
trastuzumab-based first-line therapy, we performed 
univariate analyses with various clinicopathologic and 
molecular characteristics of first-line PFS and OS (Table 3). 
In univariate analysis, SRC histology, initial presence of 
bone metastasis, poor performance status, HER2 AI <5, 
and loss of PTEN expression were predictive for shorter 
PFS in HER2+ GC patients when treated with Herceptin. 
Next, to verify independent predictive factors for primary 
resistance, we performed multivariate analyses for 
variables found to be statistically significant in univariate 
analyses. Multivariate Cox regression analysis revealed 
two independent predictors for primary resistance against 
trastuzumab-based regimen: low HER2 AI (<5) and loss of 
PTEN expression. In patients with HER2 AI <5, median 
PFS and OS of first-line therapy was lower compared to 
those with HER2 AI ≥ 5 (PFS: 4.0 vs. 9.5 months, p < 0.001; 
OS: 11.1 vs. 20.8 months, p = 0.001) (Figure 1A). 
Moreover, in patients with a loss of PTEN expression, 
median PFS and OS of first-line trastuzumab-based 
treatment was shortened compared to those with intact 
PTEN expression (PFS: 4.5 vs. 12.4 months, p = 0.004; OS: 
12.3 vs. 28.9 months, p = 0.011) (Figure 1B). 
Next, we analyzed PFS and OS according to the 
number of these risk factors that patients possessed: 0 vs. 
1 vs. 2. (Figure 1C). The most favorable survival outcome 
was seen in patients with no risk factors: median PFS 
was 9.0 months (95% CI: 6.8–11.2) and OS 20.8 months 
(95% CI: 12.8–28.7). The prognosis of patients possessing 
1 risk factor was intermediate with a median PFS of 
5.8 months (95% CI: 6.8–11.2) and OS of 15.8 months 
Table 2: Clinical response to trastuzumab-based first-line chemotherapy
HER2 AI PTEN expression
≥5 <5 Intact Loss
Best response
 CR, PR 47 (58.8%) 6 (21.4%) 36 (64.3%) 4 (36.4%)
 SD 26 (32.5%) 15 (53.6%) 15 (26.8%) 5 (45.5%)
 PD 7 (8.8%) 7 (25.0%) 5 (8.9%) 2 (18.2%)
P-value 0.002 0.220
Table 3: Univariate and multivariate analysis for PFS and OS
Univariate Multivariate
Median survival 
(months) P-value HR (95% CI) P-value
PFS
 Histology (SRC vs. non-SRC) 5.1 vs. 8.2 0.103 1.27 (0.46–3.49) 0.647
 Bone metastasis (Yes vs. No) 2.8 vs. 8.2 0.001 1.57 (0.57–4.33) 0.383
 ECOG Performance (≥1 vs. 0) 5.1 vs. 12.1 <0.001 1.14 (0.52–2.49) 0.742
 HER2 AI (<5vs. ≥5) 4.0 vs. 9.5 <0.001 3.26 (1.38–7.73) 0.007
 PTEN expression (loss vs. intact) 4.5 vs. 12.4 0.004 3.01 (1.22–7.46) 0.017
OS
 Histology (SRC vs. non-SRC) 6.5 vs. 16.4 0.010 1.58 (0.43–5.76) 0.491
 Bone metastasis (Yes vs. No) 14.6 vs. 16.9 0.009 2.21 (0.70–7.02) 0.179
 ECOG Performance (≥1 vs. 0) 9.8 vs. 23.5 <0.001 1.01 (0.37–2.74) 0.987
 HER2 AI (<5vs. ≥5) 11.1 vs. 20.8 0.001 3.23 (1.23–8.49) 0.018
 PTEN expression (loss vs. intact) 12.3 vs. 28.9 0.011 2.88 (1.02–8.10) 0.045
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(95% CI: 9.4–22.1). However, the patients with both risk 
factors had the worst prognosis with a median PFS of 2.6 
months (95% CI: 2.1–3.1) and OS of 4.8 months (95% 
CI: 0–9.9). Based on these findings, we could confirm 
that these two molecular factors are the main predictors of 
primary resistance to trastuzumab in HER2+ GC patients.
DISCUSSION
Trastuzumab is an active agent used in combination 
with chemotherapy against HER2+ metastatic GC [1]. 
Since its approval by the FDA in 2010, it is widely 
used in the treatment of metastatic HER2+ GC. In 
Eastern countries, the majority of patients treated with 
trastuzumab-based chemotherapy presented with PFS > 
6 months and OS > 12 months [17, 18]. However, some 
HER2+ GC patients exhibited primary resistance to 
trastuzumab-based regimen. These patients progressed 
rapidly within a few months of initiation of therapy, and 
eventually displayed dismal prognosis [6].
To date, HER2+ GC patients with primary 
resistance to trastuzumab have not been thoroughly 
characterized, and only a few studies on the predictive 
biomarkers for trastuzumab resistance in GC have been 
Figure 1: Survival outcomes according to molecular biomarkers in HER2+ gastric cancer. (A) PFS and OS according to 
the level of HER2 amplification (B) PFS and OS according to the presence or absence of PTEN expression (C) PFS and OS according to 
the number of molecular biomarker PFS, progression-free survival; OS, overall survival.
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reported. In the post-hoc analysis of the ToGA trial, a 
link was reported between the baseline HER2 expression 
level and trastuzumab response [3, 18]. In addition, 
Gomez-Martin et al. recently suggested that the level 
of HER2 amplification predicts treatment response 
and overall survival in GC [19]. In most recent study, 
Deguchi et al. revealed that the knockdown of PTEN 
induces trastuzumab resistance by Akt activation in 
preclinical model of GC [20]. They also reported that 
there is no clinical response in PTEN-deficient GC 
patients compared to response rate of 50% in PTEN-
positive GC patients. However, since the number of 
HER2+ patients in this study was very small (n = 23), the 
results should be interpreted with care. Moreover, there 
are reports on the relationship between PTEN expression 
and response to the trastuzumab-containing therapy in 
HER2+ breast cancer [21]. In summary, comprehensive 
studies on the potential biomarkers of HER2+ GC, 
whether they be clinical or molecular, are still lacking 
and need to be pursued.
In the present study, we found that trastuzumab-
resistant HER2+ GC patients usually presented with SRC 
histology, initial bone metastasis, poor performance status 
(ECOG ≥ 2), low HER2 AI in FISH and a loss of PTEN 
expression at diagnosis. Although we also examined the 
role of PIK3R1, the regulatory subunit of PI3K, we were 
unable to determine its role in the treatment of HER2+ GC. 
Moreover, following multivariate Cox regression analysis, 
we were able to identify two independent molecular 
predictors for resistance to first-line trastuzumab-containing 
chemotherapy: low HER2 AI (<5) and loss of PTEN 
expression. These two risk factors are also independent 
prognostic factors for OS. Patients possessing either of these 
risk factors exhibited primary resistance to trastuzumab 
and their prognosis is dismal, suggesting that this subgroup 
would benefit from other therapeutic targets. Because 
loss of PTEN expression is associated with the activation 
of PI3K signaling and mitogen-activated protein kinase 
(MAPK) pathways [22], pharmacologic inhibition of these 
pathways could provide a reasonable strategy to overcome 
trastuzumab resistance in HER2+ GC.
In this study, patients with SRC histology responded 
poorly to trastuzumab-based regimen. Previous research 
has shown that epithelial-to-mesenchymal transition 
(EMT) confers primary resistance to trastuzumab in tumor 
cells [23]. In addition, the loss of E-cadherin in gastric 
mucosal epithelial cells is a critical carcinogenic event 
that initiates gastric SRC carcinoma in humans and mice 
[24]. Therefore, primary resistance in SRC carcinoma may 
be the result of augmented EMT in E-cadherin-deficient 
SRC. More preclinical evidence is required to prove this 
inference.
The findings of this study may be limited by its 
retrospective nature. However, we believe that these 
shortcomings can be offset to a certain extent by the fact 
that more than half of the patients in this study formed part 
of well-controlled, multi-institutional prospective clinical 
trials such as the ToGA trial, and that the remaining 
patients received standardized clinical treatment at a 
single tertiary cancer center. To validate the findings of 
the present study and further characterize the biology 
of HER2+ GC, we are now planning to establish the 
multicenter prospective cohort for HER2+ GC patients in 
Korea.
In conclusion, loss of PTEN expression and low 
HER2 AI correlated with resistance to trastuzumab-based 
first-line therapy and dismal prognosis in HER2+ GC. 
Since patients harboring these molecular alterations are 
unlikely to respond to conventional trastuzumab-based 
therapy, other novel therapeutics that will benefit this 
subset need to be pursued.
MATERIALS AND METHODS
Patient selection
Patients with metastatic GC were enrolled in Yonsei 
Cancer Center, Severance Hospital, Seoul, Korea between 
December 2005 and August 2015. Patients were followed 
up until December 2016. Patient eligibility criteria were as 
follows: 1) metastatic GC patients with HER2 positivity 
defined by either HER2 3+ in immunohistochemical 
(IHC) staining, or HER2 2+ in IHC staining and HER2 
amplification on fluorescence in situ hybridization 
(FISH) (HER2:CEP17 ratio ≥2); 2) chemotherapy-naive 
patients with the exception of adjuvant chemotherapy 6 
months prior to enrollment; 3) patients who have been 
treated with palliative trastuzumab in combination with 
either 5-fluorouracil and cisplatin (FP) or capecitabine 
and cisplatin (XP). Clinicopathologic parameters were 
reviewed from the information of the electronic medical 
record system as previously described [25]. 
HER2 status in surgical or biopsy specimen were 
analyzed and determined by experienced pathologists in 
Severance Hospital, Seoul, Korea, using the HercepTest 
KitTM (DAKO, Denmark) for IHC staining and VysisTM 
HER2/CEP FISH probe kit (Abbott, USA) for FISH 
analysis according to the manufacturers’ instructions. This 
study was approved by the Institutional Review Board in 
Severance Hospital, Seoul, Korea (IRB approval number: 
4-2014-1076).
Evaluation of PTEN expression in GC tissue
Formalin-fixed paraffin-embedded sections of 
tumor tissue were deparaffinized with xylene and 
hydrated with graded alcohol. Antigen retrieval was 
performed with a retrieval solution (DAKO, USA) 
using the pressure-cooking method, and the activity of 
endogenous peroxidase was blocked by a 1:40 mixture 
of hydrogen peroxide and methanol. The primary PTEN 
antibody (DAKO) incubation was performed at room 
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temperature for 1 h in an antibody solution diluted to 
1:100. All sections were incubated at room temperature 
for 30 min in the Real EnVisionTM HRP Rabbit/Mouse 
(DAKO, USA) detection system, which functions as 
the secondary antibody. PTEN expression was indicated 
using a chromogen and counterstaining was performed 
with hematoxylin. PTEN expression was quantified by 
the H-score based on the intensity of cell staining and 
percentage of the stained cells [17]. Intensity was scored 
as 0: none, 1: weak, 2: moderate, or 3: strong. The H-score 
was calculated as follows: H-score = (%1 + cells × 1) 
+ (%2 + cells × 2) + (%3 + cells × 3). An H-score of ≤ 
10 was used as the cutoff point to define loss of PTEN 
expression based on a previous study.
PIK3R1 variant analysis
We used a pyrosequencing assay to detect variant 
alleles of PIK3R1. The primer was forward 5′ (biotin) - 
CACCAAAACCTACTACTGTAGCCAA-3′ and reverse 
5′ - GAGATATCTCCCCAGTACCATTCA-3′. Amplicon 
length was 85 bp and sequence to analyze was 5′–AGGA 
C/T ATATT-3′. Each PCR mix contained the forward and 
reverse primers, dNTP mix, MgCl2, PCR buffer, AmpliTaq 
Gold, and 100 ng of sample genomic DNA. PCR mixtures 
were denatured for 10 min at 95°C and then thermal-
cycled for 30 s at 95°C, 30 s at 55°C, and 30 s at 72°C, 
repeating the cycle 40 times. A final extension step at 
72°C for 5 min completed the program. PCR products 
were analyzed by agarose gel electrophoresis and 
sequenced using the PyroMark Q24 (QIAGEN) system 
according to the manufacturer’s instructions.
Statistical analysis
The correlation between clinicopathologic variables 
was compared using chi-square test and independent 
sample t-test. Multivariate analysis was done by logistic 
regression to identify the independent predictive factors 
for primary resistance to trastuzumab. OS was defined as 
the time interval from the date of initiation of trastuzumab-
based chemotherapy to the date of death or last follow-
up. PFS was defined as the time between initiation of 
therapy and the date of documented disease progression 
or death. All patients underwent response evaluation with 
regular CT scan at 6- to 8-week intervals for accurate PFS 
measurement. OS and PFS were compared using Kaplan-
Meier survival analyses with log-rank tests. The accepted 
level of statistical significance was p < 0.05. All statistical 
analyses were carried out with SPSS 12.0 (SPSS, Inc.).
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